HHS Won’t Enforce Peptide Rules FDA Scientists Wouldn’t Relax

FDA scientists would not give the proposed peptide policy the safety finding its authors wanted. So the Department of Health and Human Services has found something else to relax: enforcement.

Associated Press reporting published by the Guardian describes a policy posted Wednesday that directs the FDA not to act against specialty pharmacies selling a handful of unapproved wellness peptides. According to people familiar with its development, HHS initially wanted a regulation placing the substances on a list deemed safe for compounding. Agency scientists had major safety concerns and would not support that approach.

The solution was not a new body of evidence demonstrating safety and effectiveness. It was a different administrative instruction. The scientific answer remained inconvenient, so the government changed which question would determine whether the products could be sold.

This is the regulatory equivalent of failing a driving test and asking the examiner to stop watching the intersection.

The distinction matters because consumers can easily mistake permitted access for an official finding about a product. These substances, including BPC-157 and TB-500, have not been approved by the FDA as safe and effective. There are approved peptide medicines. That does not confer a family discount on the evidence required for every other peptide someone wants to sell.

Robert F. Kennedy Jr. has publicly praised peptides and described using BPC-157 for a muscle injury. His personal enthusiasm is a fact about the health secretary. It is not a clinical trial, even when delivered by somebody who can issue instructions to the department overseeing one.

The AP’s account rests on six people familiar with confidential deliberations who spoke anonymously. HHS did not immediately respond to its request for comment. That account of internal opposition is not an agency-wide public vote. The policy’s nonenforcement approach, however, is a concrete development beyond the earlier plans to expand access.

There are safeguards in it. FDA staff provided technical help, and the plan includes sourcing ingredients from FDA-registered factories, verifying chemical identity and collecting side-effect information. Those are meaningful protections. They are also different from establishing that an injection does what its promoters claim without unacceptable risks.

A label can accurately identify what is in a vial while leaving the much larger question of whether you should inject it unanswered. It is a remarkably important distinction for a health department to keep legible.

Kennedy’s stated argument is that Americans already obtain these products through a gray market, often from overseas suppliers. Moving activity into pharmacies with more controls may address some risks of that market. That argument still needs to survive contact with the safety concerns, rather than being treated as permission to declare them solved.

Nor does the reporting establish that HHS lacks legal authority to intervene. Federal law gives the department broad drug-regulation authority that is generally delegated to the FDA. The problem here is not an invented constitutional obstacle. It is the choice to use that authority to permit access without the safety conclusion scientific staff would not provide.

The government is very good at printing distinctions in small type. In this case, the essential one belongs in large type: nonenforcement is not approval. If that sentence makes the new policy harder to sell, the sentence is doing its job.